These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 8959296

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Relationship between residual symptomatology and auditory evoked potentials in schizophrenic outpatients.
    Hegerl U, Gaebel W, Ulrich G.
    Pharmacopsychiatry; 1988 Nov; 21(6):329-30. PubMed ID: 2907638
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.
    Cascella NG, Macciardi F, Cavallini C, Smeraldi E.
    J Neural Transm Gen Sect; 1994 Nov; 95(2):105-11. PubMed ID: 7865165
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The Psychiatric Symptom Assessment Scale (PSAS).
    Bigelow LB, Berthot BD.
    Psychopharmacol Bull; 1989 Nov; 25(2):168-73. PubMed ID: 2574891
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study.
    Lotstra F, Verbanck P, Mendlewicz J, Vanderhaeghen JJ.
    Biol Psychiatry; 1984 Jun; 19(6):877-82. PubMed ID: 6378259
    [No Abstract] [Full Text] [Related]

  • 31. [Experiences with hemofiltration/hemodialysis in schizophrenias].
    Ernst K, Börner I, Herbst A, Klinkmann H, Lindenau K, Osten B, Precht K, Schläfke D, Seidel M.
    Samml Zwangl Abh Geb Psychiatr Neurol; 1982 Jun; 50():114-23. PubMed ID: 6130611
    [No Abstract] [Full Text] [Related]

  • 32. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia.
    Rosse RB, Fay-McCarthy M, Kendrick K, Davis RE, Deutsch SI.
    Clin Neuropharmacol; 1996 Oct; 19(5):444-50. PubMed ID: 8889288
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Serum cholesterol and treatment-resistance in schizophrenia.
    Boston PF, Dursun SM, Zafar R, Reveley MA.
    Biol Psychiatry; 1996 Sep 15; 40(6):542-3. PubMed ID: 8879475
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia.
    Sirota P, Epstein B, Benatov R, Sousnostzky M, Kindler S.
    J Clin Psychopharmacol; 2001 Aug 15; 21(4):454-5. PubMed ID: 11476132
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.